Clinical Trials
628 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
National Institutes of Health Clinical Center (CC)
DOTA-STR-17126
Integrated Haematology and Oncology Network
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
FOCUS
Ohio State University Comprehensive Cancer Center
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
SABRE
Boston Scientific Corporation
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
CASSETTE
University of Southampton
EV-309
Astellas Pharma Inc
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
University of Alicante
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
AxeCan
HealthPartners Institute
ReplaceCysto
White River Junction Veterans Affairs Medical Center
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
LIAM Mc
University College Cork
Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology
UNC Lineberger Comprehensive Cancer Center
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
FC-VE
University Hospital, Linkoeping
CARE Tool Study Aim 3
Washington University School of Medicine
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
PATH
VA Office of Research and Development
P300
Pathos AI, Inc.
AH-HA
Wake Forest University Health Sciences
FASN
Wake Forest University Health Sciences
ReRT
The New York Proton Center
VICKI
Institut Mutualiste Montsouris
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
HypProMet
Saint-Gregoire Private Hospital Center
VIOLETTE
Koelis
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
ACCESS-PC
Rutgers, The State University of New Jersey
STRIKE-001
K36 Therapeutics, Inc.
HACER
University of Arizona
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
ADVANCED-3
Protara Therapeutics
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
BOOST
Relmada Therapeutics, Inc.